These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29951728)

  • 1. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
    Hasinoff BB; Patel D
    Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.
    Hasinoff BB; Patel D; Wu X
    Cardiovasc Toxicol; 2017 Jul; 17(3):237-250. PubMed ID: 27388042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome.
    Hasinoff BB
    Arch Biochem Biophys; 2018 Feb; 639():52-58. PubMed ID: 29305052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors.
    Teicher BA; Tomaszewski JE
    Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Pokorna Z; Jirkovsky E; Hlavackova M; Jansova H; Jirkovska A; Lencova-Popelova O; Brazdova P; Kubes J; Sotakova-Kasparova D; Mazurova Y; Adamcova M; Vostatkova L; Holzerova K; Kolar F; Simunek T; Sterba M
    Clin Sci (Lond); 2019 Aug; 133(16):1827-1844. PubMed ID: 31409729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
    Patatsos K; Shekhar TM; Hawkins CJ
    Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity.
    Hasinoff BB; Patel D
    Arch Biochem Biophys; 2017 Nov; 633():23-28. PubMed ID: 28887129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second Generation Proteasome Inhibitors in Multiple Myeloma.
    Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
    Zang Y; Kirk CJ; Johnson DE
    Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
    Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
    Autophagy; 2012 Dec; 8(12):1873-4. PubMed ID: 22995770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and Death.
    Sanchez G; Berrios D; Olmedo I; Pezoa J; Riquelme JA; Montecinos L; Pedrozo Z; Donoso P
    PLoS One; 2016; 11(8):e0161068. PubMed ID: 27529620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
    Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative mechanisms of action of proteasome inhibitors.
    Wang M
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitor-induced gastrointestinal toxicity.
    Stansborough RL; Gibson RJ
    Curr Opin Support Palliat Care; 2017 Jun; 11(2):133-137. PubMed ID: 28333868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.